BackgroundAtrial electromechanical delay (EMD) is used to predict atrial fibrillation,
measured by echocardiography.ObjectivesThe aim of this study was to assess atrial EMD and mechanical function after
anthracycline-containing chemotherapy.MethodsFifty-three patients with breast cancer (48 ± 8 years old) who
received 240 mg/m2of Adriamycin, 2400 mg/m2 of
cyclophosphamide, and 960 mg/m2 of paclitaxel were included in
this retrospective study, as were 42 healthy subjects (47 ± 9 years
old). Echocardiographic measurements were performed 11 ± 7 months
(median 9 months) after treatment with anthracyclines.ResultsLeft intra-atrial EMD (11.4 ± 6.0 vs. 8.1 ± 4.9, p=0.008) and
inter-atrial EMD (19.7 ± 7.4 vs. 14.7 ± 6.5, p=0.001) were
prolonged; LA passive emptying volume and fraction were decreased (p=0.0001
and p=0.0001); LA active emptying volume and fraction were increased
(p=0.0001 and p=0.0001); Mitral A velocity (0.8 ± 0.2 vs. 0.6
± 0.2, p=0.0001) and mitral E-wave deceleration time (201.2 ±
35.6 vs. 163.7 ± 21.8, p=0.0001) were increased; Mitral E/A ratio
(1.0 ± 0.3 vs. 1.3 ± 0.3, p=0.0001) and mitral Em (0.09
± 0.03 vs. 0.11 ± 0.03, p=0.001) were decreased; Mitral Am
(0.11 ± 0.02 vs. 0.09 ± 0.02, p=0.0001) and mitral E/Em ratio
(8.8 ± 3.2 vs. 7.6 ± 2.6, p=0.017) were increased in the
patients.ConclusionsIn patients with breast cancer after anthracycline therapy: Left
intra-atrial, inter-atrial electromechanical intervals were prolonged.
Diastolic function was impaired. Impaired left ventricular relaxation and
left atrial electrical conduction could be contributing to the development
of atrial arrhythmias.